Fifty-one Kaposi sarcoma patients
- 50 Downloads
Kaposi sarcoma (KS) is a mesenchymal tumor originating from lymphatic endothelial cells. Immunsupressive patients have higher risk for KS. HHV-8 has a role in immunpathogenesis of KS.
Evaluation of demographical properties with tumor characteristics and treatment modalities of KS.
Material and method
Histopathologically documented KS patients were evaluated retrospectively. Anti-HIV seroprevalence was also evaluated with patient and tumor characteristics besides treatment regimens.
Fifty-one patients were included between September 1998 and February 2009. Male/female ratio was 3.25 (39/12). Median age was 68 (31–94). Lower extremity was the most common site whereas excisional biopsy was the most common diagnostic procedure. Smoking rate was 42.8%. Twenty percent had family history for cancer. Anti-HIV seropositivity rate was 1.9%. Thirty eight percent had local monotherapy, and radiotherapy was most common (26%). Multidisciplinary approach rate was 44%. Most of them had surgery and radiotherapy combination. Two-third of the patients had radiotherapy alone or with other modalities. Rates were as 12% for chemotherapy and 6% for interferon. Vincristine-bleomycin-doxorubicin combination was the most preferred regimen (60%).
Male patients in the sixth decade seem to have higher risk for KS. Smoking rate was almost as high. Local therapy might be sufficient in most of the patients. However, we may also consider systemic chemotherapy for selected patients, including vincristine, bleomycin and doxorubicin.
KeywordsKaposi sarcoma Treatment of Kaposi sarcoma Chemotherapy in Kaposi sarcoma Interferon in Kaposi sarcoma
Unable to display preview. Download preview PDF.
- 1.Wang HW, Trotter MW, Lagos D et al (2004) Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. Nat Genet 36:693Google Scholar
- 6.Mann DL, Murray C, O’Donnell M (1990) HLA antigen frequencies in HIV-1-related Kaposi sarcoma. J Acquir Immune Defic Synd 3:51–55Google Scholar
- 10.Wen KW, Damania B (2009) Kaposi sarcoma-associated herpesvirus (KSHV): molecular biology and oncogenesis. Cancer Lett doi: 10.1016/j.canlet.2009.07.004Google Scholar
- 19.Ramirez-Rodriguez JM, Morgan-Villela G, Robles-Toscano JA, Echeagaray E (1996) Therapeutic response of the epidemic Kaposi Sarcoma. Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother 212 (abstract I142)Google Scholar